This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The intervention was screening for the CCR5 deletion 32 polymorphism, followed by treatment for dialysis patients with the CCR5 insertion/insertion genotype, who had systemic inflammation, using pharmacological CCR5 blockers. The comparator was no screening.
Location/setting
Netherlands/secondary and tertiary care.
Methods

Analytical approach:
The analysis was based on a Markov model, with a 10-year time horizon. The authors stated that it was carried out from the perspective of the third-party health care payer.
Effectiveness data:
Most of the clinical data were from a published multicentre, prospective follow-up study that was part of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD). This study enrolled 413 patients with incident (new or consecutive) end-stage renal disease, who were treated at one of 38 Dutch dialysis centres between 1998 and 2001. It provided data on the genotype distribution and the efficacy of CCR5 blockers. Patients were followed-up until their death or until June 2007. Inflammation-associated mortality was a key clinical input and the data were from this study. Additional published sources were used for other inputs.
Monetary benefit and utility valuations:
The health utility values were collected from patients in the NECOSAD study, using the European Quality of life (EQ-5D) instrument. The utilities for transplanted patients were from a Swedish study.
Measure of benefit:
Life-years and quality-adjusted life-years (QALYs) were the summary benefit measures. A 1.5% annual discount rate was applied.
